Scivita Medical enters into Strategic Agreement with Boston Scientific in China
SUZHOU, China, March 29, 2023 /PRNewswire/ -- Medical technology company Scivita Medical Technology Co., Ltd. ('Scivita Medical') and Boston Scientific (NYSE: BSX), one of the leading medical technology companies worldwide, have officially signed a Strategic Agreement for Scivita's Single-Use Percutaneous Choledochoscope. Through this business cooperation and distribution agreement, Scivita Medical and Boston Scientific plan to establish a long-term partnership...
Just Three Months Into 2023, United Imaging Says Four New Scanners in Multiple Imaging Modalities Are Now Commercially Available in the United States
The products expand the company's success in outpatient imaging and bring new benefits to the acute care and academic segments. HOUSTON, March 29, 2023 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, announced that four new scanners are already commercially available in 2023, three of them having received FDA clearance within...
HanAll Biopharma Assigns Su-jin Park as Co-CEO to Drive Next Phase of Growth
Su-jin Park joins HanAll Biopharma in a shared leadership role to strengthen pharmaceutical business in Korea, supporting growth in domestic drug sales Sean Jeong, who has been serving as Co-CEO since March 2021, will continue to lead HanAll's R&D, including its subsidiary HanAll Pharmaceutical International in the U.S. The new Co-CEO,...
Fosun Pharma Announces its 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public
SHANGHAI, March 29, 2023 /PRNewswire/ -- On March 27, 2023, the release date of its 2022 Annual Report, Fosun Pharma (stock code: 600196.SH; 02196.HK) also released the 2022 Corporate Social Responsibility Report, its 15th CSR report since the first which was issued in 2009. As before, Fosun Pharma achieved a five-star rating, as evaluated by the China CSR Report Rating...
Transcenta’s Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer
SUZHOU, China, March 29, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Osemitamab (TST001), its high affinity humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody, for the treatment of...
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia
Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. The Phase I CLINCH trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 monotherapy in patients with advanced or metastatic solid tumors. ATG-022 has also...
Innovent Announces 2022 Annual Results and Business Updates
Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capability ROCKVILLE, Md. and SUZHOU, China, March 29, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, announces its 2022 annual results and major company business...
Verbal Beginnings partners with The Clinician to launch a Patient Reported Outcomes Program for Children with Autism Spectrum Disorder
COLUMBIA, Md., March 29, 2023 /PRNewswire/ -- A leading US-based Applied Behavior Analysis (ABA) therapy provider, Verbal Beginnings, has partnered with The Clinician, a global healthcare company, to pilot a patient reported outcome measures (PROMs) program for children with Autism Spectrum Disorder (ASD). The program aims to support Verbal Beginnings in the delivery...
Healthcare Revolution: Medical Tourism and the American Dream
PALM BEACH GARDENS, Fla., March 28, 2023 /PRNewswire/ -- The 15th annual Healthcare Revolution (May 23, 2023), the largest confluence of thought leaders in the world of healthcare, self-funded employers, brokers, and healthcare leaders, has launched, and this time with thought-provoking and insightful discussions about how self-funded employers can leverage medical tourism to achieve great healthcare outcomes for their...
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
SUZHOU, China, March 28, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 740 subjects recently for the Phase III clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China for the treatment of male androgenetic...
